Effects of the selective phosphodiesterase type 5 inhibitor sildenafil citrate [sildenafil] on exercise capacity and vascular function in hypertensive subjects
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2010
At a glance
- Drugs Sildenafil (Primary) ; Hydralazine
- Indications Hypertension
- Focus Pharmacodynamics
- 09 Apr 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 09 Apr 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.
- 09 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.